-
Nutrition and Type 1 Diabetes: Supporting Safe and Sustainable Weight Loss
I recently had the opportunity to contribute to an upcoming text from the American Diabetes Association on nutrition therapy in diabetes care. Specifically, I was tasked with reviewing and rewriting a chapter on nutrition recommendations for adults with type 1 diabetes and insulin-requiring type 2. In my excitement for its upcoming publication, I wanted to share a preview of what makes weight and fat loss in type 1 diabetes uniquely complex and highlight evidence-based strategies for supporting safe, sustainable weight management in this population. I hope this sneak peek sparks curiosity and encourages you to consider adding this valuable resource…
-
How Virtual Dietitians Are Expanding Access to Diabetes Care
For years, nutrition support has been an essential but underutilized part of diabetes care. Despite strong evidence that medical nutrition therapy improves outcomes, many people with diabetes have faced challenges accessing consistent, high-quality guidance from registered dietitians. That’s beginning to change. Virtual care is breaking down long-standing barriers, making it easier to connect with dietitians in timely, flexible, and personalized ways. As a result, virtual dietitians are helping close critical gaps in care, and nutrition counseling is becoming more central and more accessible than ever before.
-
Goodbye BMI? Why Body Composition Is Gaining Ground in Clinics
The rise of incretin-based therapies for obesity care, like Wegovy (semaglutide) and Zepbound (tirzepatide), has brought renewed attention to the risk of muscle atrophy that can accompany rapid weight loss. To better assess changes in skeletal muscle mass, clinicians are turning to body composition assessment tools to track progress over time. However, the ability to measure, interpret, and communicate changes in body composition is a skill most clinicians haven’t been formally trained in, leaving many feeling like it’s not a tool they can confidently use. I want to push back against that assumption and offer some basic principles to help…
-
GLP-1 Success Starts with Dietitian Leadership
It should come as no surprise that a large part of the success with incretin-based therapies— like Ozempic, Wegovy, Mounjaro, and Zepbound—stems from the effective integration of lifestyle modifications, particularly nutrition. This success occurs at both the individual and programmatic levels. But it’s not always for the reasons you might expect. By the time most people begin incretin-based therapy, especially for weight management, they’ve often already tried a range of diets: calorie counting, commercial weight loss programs like Jenny Craig or Weight Watchers, and more. This time, they’re looking for something different—something that addresses the deeper pathophysiology and root causes…
-
GLP-1 Therapy Part 2: Preventing and Managing Side Effects
I recently had the pleasure of presenting at the Colorado Academy of Nutrition and Dietetics Annual Conference on the topic of nutrition strategies for effective GLP-1 use in obesity treatment. This premier event, dedicated to supporting nutrition and dietetics professionals in Colorado, offered a valuable opportunity to share updated evidence on GLP-1 therapies, while also debunking common myths to promote informed and unbiased nutrition counseling. In this four-part series, I’m excited to share my key recommendations to help support your practice. In Part 2, we’ll discuss strategies for managing and preventing medication-related side effects New to this series? Start with…
-
GLP-1 Therapy Part 1: Setting Realistic Weight Loss Expectations
I recently had the pleasure of speaking at the Colorado Academy of Nutrition and Dietetics Annual Conference on the topic of nutrition strategies for effective GLP-1 use in obesity treatment. This premier event, dedicated to supporting nutrition and dietetics professionals in Colorado, offered a valuable opportunity to share updated evidence on GLP-1 therapies, while also debunking common myths to promote informed and unbiased nutrition counseling. In this four-part series, I’m excited to share my key recommendations to help support your practice. In Part 1, we’ll explore key considerations for identifying appropriate GLP-1 candidates and highlight the importance of setting realistic…
-
Mitigating Therapeutic Inertia of GLP-1 Use in T2D
Glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 RAs, have recently garnered significant media attention. Initially developed to improve glycemic control in patients with type 2 diabetes, these medications have also proven to be highly effective for weight loss and enhancing cardiovascular health. However, without proper initiation, titration, and support from the care team, they can often be ineffective and unsustainable. Patients can become stuck in therapeutic inertia. I had the pleasure of presenting on this topic with a pharmacy colleague at this year’s ADCES Annual Conference for diabetes care and education specialists. Here’s how we identified and provided solutions…
-
GLP-1 Injectables for Older Adults
With the increasing interest in and popularity of GLP-1 injectable medications, there is a growing concern about their safety when used with older adults. This article reviews some of the benefits and concerns associated with the use of GLP-1 injectable medications in advanced age. Are GLP-1’s Appropriate for Older Adults? In general, age is not a contraindication to using GLP-1 medications. Individuals of any age can experience weight loss and improved metabolic health with a once-weekly injectable. In fact, medications like Ozempic or Trulicity can be safer options compared to others such as insulin or sulfonylureas, as they rarely cause…
